“We saw strong progress in the first quarter across our clinical pipeline, next generation of therapeutic programs, and advancing our platform,” said Mike Nally, chief executive officer of Generate Biomedicines (GENB), Inc. “We are advancing GB-0895 in Phase 3 for severe asthma and Phase 1b for COPD. In oncology, we expect to progress two clinical trials this year with GB-4362, an MMAE neutralizer, and GB-5267, a MUC16 CAR T developed with Roswell Park. Together, these programs reflect the breadth of our clinical portfolio across therapeutic areas, modalities, and both wholly owned and partnered programs.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GENB:
- Generate Biomedicines initiated with a Buy at H.C. Wainwright
- Buy Rating on Generate Biomedicines Driven by Differentiated Pipeline, GB-0895 Asthma Opportunity, and AI-Enabled Protein Platform
- Generate Biomedicines: Differentiated AI-Driven Protein Platform with GB-0895 Asthma Lead and Emerging Oncology Upside Justifies Buy Rating
- Generate Biomedicines initiated with an Overweight at Cantor Fitzgerald
- Generate Biomedicines initiated with a Buy at Guggenheim